Biogen Idec
Links shared publicly online about this topic
Biogen Idec's Fampyra approved in Australia
boston.com — “Biogen Idec Inc. said that Australian regulators approved marketing of its multiple sclerosis drug Fampyra.” View full resource at boston.com
Most Recently Shared on May 16, 2011 at 2:32 pm By:
Biogen Idec's Fampyra approved in Australia: Biogen Idec Inc. said that Australian regulators approved marketing ... http://bo.st/loIdeO
Biogen Idec acquires Neurimmune subsidiary
news-medical.net — “Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43.” View full resource at news-medical.net
Most Recently Shared on December 21, 2010 at 10:30 am By:
Parkinson's Disease: Biogen Idec acquires Neurimmune subsidiary: Biogen Idec and Neurimmune Holding AG today ann... http://bit.ly/eguDEu
Biogen Idec to rearrange drug lineup - The Boston Globe
boston.com — “CAMBRIDGE — Scientists at Biogen Idec Inc.’s warren of research labs in Kendall Square are working to discover treatments for diseases ranging from lupus to multiple sclerosis.” View full resource at boston.com
Most Recently Shared on October 6, 2010 at 3:27 pm By:
John Carroll Health Communicator
Biogen Idec's new chief is planning a big revamp of R&D, with more collaborations involving small biotechs. http://bit.ly/bhasKw
Biogen Idec And Neurimmune Announce Agreement On Three Neurodegenerative Disease Programs
medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) and Neurimmune Holding AG have announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunother” View full resource at medicalnewstoday.com
Most Recently Shared on December 22, 2010 at 2:05 pm By:
MNT Pharma News Health News and Pharma
Biogen Idec And Neurimmune Announce Agreement On Three Neurodegenerative Disease Programs http://mnt.to/3Pp8 #pharma #pharmaceutical
Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia
medicalnewstoday.com — “Genentech, inc., a wholly-owned member of the roche group (six: ro, rog; otcqx: rhhby), and biogen idec (nasdaq: biib) announced today that the u.s. food and drug administration (fda) issued a com” View full resource at medicalnewstoday.com
Most Recently Shared on November 20, 2009 at 9:20 am By:
Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia.. http://tinyurl.com/yhx227f
UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323
medicalnewstoday.com — “UCB and Biogen Idec announced the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that” View full resource at medicalnewstoday.com
Most Recently Shared on July 1, 2009 at 3:10 pm By:
MedNewsToday: UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323: UCB and Biogen Ide.. http://tinyurl.com/my5fdm
IngentaConnect Roche and Biogen Idec have announced that they will discontinue t...
ingentaconnect.com — “IngentaConnect Roche and Biogen Idec have announced that they will discontinue t...” View full resource at ingentaconnect.com
Most Recently Shared on June 7, 2010 at 6:56 pm By:
Roche and Biogen Idec have announced that they will discontinue the ocrelizumab clinical development programme in ... http://bit.ly/b5zmZk
Biogen Idec And Abbott Announce Positive Top-Line Results
abbott.com — “Biogen Idec And Abbott Announce Positive Top-Line Results” View full resource at abbott.com
Most Recently Shared on August 9, 2011 at 1:59 pm By:
eyeonfda Pharma and Health Lawyer
Biogen Idec & Abbott announce topline Ph 2b results from daclizumab HYP trial 4 relapse-remitting multiple sclerosis - http://ow.ly/5YIqm
Biogen Idec introduces Tysabri for multiple sclerosis - World News, 111989
newkerala.com — “Biogen Idec introduces Tysabri for multiple sclerosis - Mumbai, Dec 24 : Biogen Idec has, a leading drug manufacturer, has announced the introduction of Tysabri (natalizumab) the first humanized, monoclonal antibody for the treatment of relapsing remitting multiple sclerosis (MS) in India.” View full resource at newkerala.com
Most Recently Shared on December 24, 2010 at 10:29 pm By:
Biogen Idec introduces Tysabri for multiple sclerosis: Mumbai, Dec 24 : Biogen Idec has, a leading drug manufact... http://bit.ly/i4woPc
Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola
news-medical.net — “Biogen Idec and Portola Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).” View full resource at news-medical.net
Most Recently Shared on October 28, 2011 at 11:46 am By:
News-Medical.Net Health News and Oncology
Oncology News: Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola: Biogen Idec ... http://t.co/rzKghZxT
Unilabs Announces Alliance in Companion Diagnostic Testing with Biogen Idec | IVD Technology
ivdtechnology.com — “Unilabs has been selected by Biogen Idec to provide a companion diagnostic anti-JCV antibody assay test, called STRATIFY-JCV. The test is a two-step ELISA assay used to detect anti-JCV antibodies. The presence of anti-JCV antibodies is one in a three-factor risk stratification algorithm, along with prior immunosuppressant use and treatment duration, used to calculate the risk of TYSABRI-treated patients developing progressive multifocal leukoencephalopathy (PML).” View full resource at ivdtechnology.com
Most Recently Shared on July 6, 2011 at 7:05 pm By:
IVD Technology Health Magazine
Unilabs Announces Alliance in Companion Diagnostic Testing with Biogen Idec http://tinyurl.com/3nduc3t
Biogen Idec Takes Option to MAKScientific MS Program - MarketWatch
marketwatch.com — “Biogen Idec Takes Option to MAKScientific MS Program - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on March 14, 2012 at 3:56 pm By:
Lisa Jarvis Science Enthusiast
Biogen licenses MAKScientific compounds targeting cannabinoid pathways for MS & other neuro diseases: http://t.co/lEI8ZXRA $BIIB
Biogen Idec arthritis model gets personal - FierceBiotechIT
fiercebiotechit.com — “Using a patient dataset and some high-horsepower computing, researchers at Biogen Idec ($BIIB) and analytics company GNS Healthcare have built a rheumatoid arthritis disease model that lets them run... Read more...” View full resource at fiercebiotechit.com
Most Recently Shared on March 15, 2011 at 2:14 pm By:
ScienceintheTriangle Science Enthusiast
Biogen Idec and partner built rheumatoid arthritis model to run patient-specific virtual clinical trials. http://bit.ly/hSFRjK #SITT
Biogen Idec buys neurodegenerative disease rights | InPharm
inpharm.com — “InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.” View full resource at inpharm.com
Most Recently Shared on December 21, 2010 at 11:06 am By:
Pharmafocus Health News and Pharma
Biogen Idec buys neurodegenerative disease rights http://goo.gl/fb/5ogj1
Why Biogen Idec Got Out of the Corporate VC Business | Xconomy
xconomy.com — “Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as” View full resource at xconomy.com
Most Recently Shared on January 27, 2012 at 3:05 pm By:
RT @ldtimmerman: Why Biogen Idec got out of the corporate VC business when so many pharmas are getting in http://t.co/nBN1x0Gy
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
OrganizedWisdom MS
Organizing multiple sclerosis resources shared by health experts, advocates, and organizations into WisdomCards.
-
News-Medical.Net
Stay up to date with the latest Parkinson's Disease news and research via News-Medical.Net
-
John Carroll
John Carroll is editor of FierceBiotech, where he primarily covers drug development and has for the past eight years.
Advertisement
